Edition:
United Kingdom

Indivior PLC (INDV.L)

INDV.L on London Stock Exchange

56.70GBp
16 Aug 2019
Change (% chg)

2.20 (+4.04%)
Prev Close
54.50
Open
53.14
Day's High
57.08
Day's Low
53.00
Volume
1,531,432
Avg. Vol
7,273,668
52-wk High
286.70
52-wk Low
20.98

About

Indivior PLC (Indivior) is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence (the Indivior Business). Its treatment and pipeline focus is opioid use disorder, alcohol use disorder, overdose rescue... (more)

Overall

Beta: 1.06
Market Cap(Mil.): £405.55
Shares Outstanding(Mil.): 730.04
Dividend: --
Yield (%): --

Financials

  INDV.L Industry Sector
P/E (TTM): 2.07 29.73 33.85
EPS (TTM): 0.27 -- --
ROI: 32.23 13.04 12.69
ROE: 1,556.25 14.12 17.13

Indivior posts 14% rise in quarterly profit

July 31 Drugmaker Indivior Plc reported a 14% rise in quarterly profit on Wednesday, as its best-selling opioid addiction drug Suboxone lost market share to generic rivals at a slower pace, than the company's previous modelling had expected.

31 Jul 2019

Indivior loses appeal to block generic Suboxone opioid treatments

A divided federal appeals court on Friday ruled against Indivior Plc in its bid to stop Dr. Reddy's Laboratories Ltd and Alvogen from selling generic versions of its opioid addiction treatment Suboxone film that infringed its patents.

13 Jul 2019

UPDATE 1-Indivior loses appeal to block generic Suboxone opioid treatments

July 12 A divided federal appeals court on Friday ruled against Indivior Plc in its bid to stop Dr. Reddy's Laboratories Ltd and Alvogen from selling generic versions of its opioid addiction treatment Suboxone film that infringed its patents.

12 Jul 2019

Indivior loses appeal to block generic Suboxone opioid treatments

July 12 A divided federal appeals court on Friday ruled against Indivior Plc in its bid to stop Dr. Reddy's Laboratories Ltd and Alvogen from selling generic versions of its opioid addiction treatment Suboxone film that infringed its patents.

12 Jul 2019

Indivior signs deal to sell schizophrenia drug in Canada

British drugmaker Indivior Plc on Thursday signed a licensing agreement with HLS Therapeutics Inc for the sale of its schizophrenia drug Perseris in Canada.

09 May 2019

Indivior signs deal to sell schizophrenia drug in Canada

May 9 British drugmaker Indivior Plc on Thursday signed a licensing agreement with HLS Therapeutics Inc for the sale of its schizophrenia drug Perseris in Canada.

09 May 2019

Indivior's Suboxone decline slower than feared as company bets on new opioid drug

Indivior Plc's best selling drug is losing market share slower than some analysts had predicted and its new drug is performing on target, lifting shares in the company despite its forecast of a possible loss this year.

02 May 2019

Indivior's Suboxone decline slower than feared as company bets on new opioid drug

Indivior Plc's best selling drug is losing market share slower than some analysts had predicted and its new drug is performing on target, lifting shares in the company despite its forecast of a possible loss this year.

02 May 2019

UPDATE 3-Indivior's Suboxone decline slower than feared as company bets on new opioid drug

* Stock closes up 5.2 percent (Adds graphics, CFO comment, details on DoJ investigation)

02 May 2019

Indivior shares plummet, Reckitt hurt on U.S. charges over opioid prescriptions

(This April 10 story refiles to fix scrambled syntax in paragraph five)

11 Apr 2019
Reuters.com is improving our Quote page. Click here to take a look and let us know what you think.

Earnings vs. Estimates